About us

Established in 2000, Biopartners’ aim is to be a leader in developing and commercializing innovative formulations and novel delivery systems of first-generation biopharmaceuticals for which there are substantial unmet patients/medical needs. Biopartners seeks to offer safe, efficacious and competitively priced biopharmaceutical therapies. Its product portfolio covers the fields of endocrinology, multiple sclerosis and virology.

With its Head Office located in Switzerland, and an affiliate located in Germany, Biopartners is building an international network through a series of collaborations and partnerships with leading development and service partners. Biopartners is in the process of negotiating commercial agreements with major companies for the distribution of products in all relevant markets.

Biopartners is owned by Bioton S.A, a dynamically-growing Polish biotechnology company, manufacturing clinically important drugs such as recombinant human insulin.

Current CEO Dr Conrad Savoy and Jean-Noël Treilles talk about the company and products in a short video